Skip to main content
. 2021 Feb 17;201:23–29. doi: 10.1016/j.thromres.2021.02.010

Table 1.

Main characteristics of the included studies in our-analysis.

Study Date Region Period Sample size
Male:N(%)
Age:mean ± SD
Newcastle-Ottawa Scale(NOS)
Total Non-survivor Survivor Total Non-survivor Survivor Total Non-survivor Survivor
Liu,X. 2020/4/24 China -2020/3/11 47 47 0 32(68%) 32(68%) 6
Lu, J. 2020/4/15 China 2020/1–2020/3 73 73 0 40(54.8%) 40(54.8%) 58.4 ± 11.5 58.4 ± 11.5 6
Qin,W. 2020/8/11 China 2019/12–2020/2 582 63 519 293(50.3%) 45(71.4%) 248(47.8%) 63 ± 12.6 71 ± 10.6 61 ± 12.6 8
Bao, C.Q. 2020/7/23 China 2020/2/10–2020/3/15 178 7 171 106(60.0%) 62.7 ± 12.0 7
Deng, Y. 2020/3/27 China 2020/1/1–2020/2/21 225 109 116 124(55.1%) 73 (67.0%) 51 (44.0%) 55.3 ± 13.4 68.3 ± 9.0 43.3 ± 18.0 8
Helms, J. 2020/5/6 France 2020/3/3–2020/3/31 150 122(81.3%) 62.3 ± 13.5 7
Liao, D.Y. 2020/7/14 China 2020/1/23–2020/2/23 231 55 176 137(59.3%) 40(72.7%) 97(55.1%) 68 ± 13.4 70 ± 11.4 66.8 ± 14.0 8
Lodigiani, C. 2020/5/1 Italy 2020/2/13–2020/4/10 388 264(68.0%) 65.3 ± 14.9 7
Martín-Rojas, R. M. 2020/8/5 Spain 2020/4/3–2020/5/3 206 18 188 131(63.6%) 11(61.1%) 120(63.8%) 63.6 ± 13.4 76.0 ± 12.3 62.4 ± 12.9 8
Mazzaccaro, D. 2020/6/12 Italy 2020/3/18–2020/4/20 32 23(71.9%) 68.6 ± 12 7
Tang, N. 2020/2/20 China 2020/1/1–2020/2/3 183 21 162 98(53.6%) 16(76.2%) 82(50.6%) 54.1 ± 16.2 64.0 ± 20.7 52.4 ± 15.6 8
Nowak, B. 2020/5/19 Poland 2020/3/16–2020/4/7 169 46 123 87(51.5%) 30 (65.2%) 57 (46.3%) 63.7 ± 19.6 75.3 ± 11.9 59.3 ± 20.1 8
Fogarty, H. 2020/6/1 Ireland 2020/3/13–2020/4/10 83 33 50 55(66.3%) 22(66.7%) 33(66%) 62 ± 16.3 67.9 ± 11.9 60.5 ± 17.7 8
Guan, W. J. 2020/2/29 China 2019/12/11–2020/1/29 1099 926 173 637(58.0%) 46.7 ± 17.1 8